Teva launches generic Adenoscan in U.S.

|About: Teva Pharmaceutical Industr... (TEVA)|By:, SA News Editor

Teva (TEVA) announces the U.S. launch of generic Adenoscan, the arrhythmias treatment marketed by Astellas Pharma (ALPMF.PK, ALPMY.PK).

TEVA enjoys 180 days of market exclusivity by virtue of being first to file.

Adenoscan has annual U.S. sales of around $65M. (PR)